RGRX Stock Overview
A biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
RegeneRx Biopharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0014 |
52 Week High | US$0.062 |
52 Week Low | US$0.0004 |
Beta | 0 |
11 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | 600.00% |
33 Year Change | -99.99% |
5 Year Change | -99.99% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
RGRX | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -1.4% | -1.9% |
1Y | 600.0% | 20.2% | 30.4% |
Return vs Industry: RGRX exceeded the US Biotechs industry which returned 20.2% over the past year.
Return vs Market: RGRX exceeded the US Market which returned 30.4% over the past year.
Price Volatility
RGRX volatility | |
---|---|
RGRX Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 9.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RGRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RGRX's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1982 | 3 | J. Finkelstein | www.regenerx.com |
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee’s Pharmaceutical Group and HLB Therapeutics.
RegeneRx Biopharmaceuticals, Inc. Fundamentals Summary
RGRX fundamental statistics | |
---|---|
Market cap | US$2.11k |
Earnings (TTM) | -US$1.69m |
Revenue (TTM) | US$76.76k |
0.0x
P/S Ratio0.0x
P/E RatioIs RGRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RGRX income statement (TTM) | |
---|---|
Revenue | US$76.76k |
Cost of Revenue | US$0 |
Gross Profit | US$76.76k |
Other Expenses | US$1.77m |
Earnings | -US$1.69m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did RGRX perform over the long term?
See historical performance and comparison